Figure 3.
Systemic IL-1β potentiates brain edema and blood–brain barrier permeability after MCAo. Recombinant IL-1β was administered systemically at the onset of MCAo, and the temporal progression of ischemic damage, brain edema, and BBB disruption were assessed. A, IL-1β significantly exacerbated ischemic damage 24 h after MCAo but not 4 and 8 h after MCAo. B, IL-1β significantly increased the extent of edema 8 and 24 h after MCAo. C, Representative brain sections immunostained for IgG. IL-1β markedly increased the intensity and distribution of IgG immunoreactivity 8 and 24 h after MCAo, indicating potentiation of BBB disruption by IL-1β. *p < 0.05, **p < 0.01 versus vehicle (veh), Student's t test. Data are presented as mean ± SEM. Scale bar, 1 mm. n = 6–8 per group.